Escate Rafael, Mata Pedro, Cepeda Jose Maria, Padreó Teresa, Badimon Lina
Catalan Institute of Cardiovascular Sciences (ICCC), Sant Pau Biomedical Research Institute (IIB-Sant Pau) Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Hospital de Sant Pau, Barcelona, Spain.
Fundacion Hipercolesterolemia Familiar, Madrid, Spain.
FASEB J. 2018 Feb;32(2):601-612. doi: 10.1096/fj.201700476R.
Familial hypercholesterolemia (FH) conveys a high risk of premature atherosclerosis as a result of lifelong exposure to high LDL cholesterol levels that are not fully reduced by standard-of-care lipid-lowering treatment. Inflammatory mediators have played a role in the progression of atherosclerotic lesions. Here, we investigated whether innate immunity cells in patients with FH have a specific proinflammatory phenotype that is distinct from that of cells in normal participants. To this end, miR-505-3p-a microRNA related to chronic inflammation-and its target genes were investigated in monocyte-derived macrophages (MACs) of patients with FH (FH-MACs) and non-FH controls (co-MACs). On the basis of the profiler PCR array analysis of agomiR-505-3p-transfected MACs, we identified the chemokine receptors, CCR3, CCR4, and CXCR1, as genes that are regulated by miR-505-3p via the transcription factor, RUNX1. miR-505-3p was significantly down-regulated, whereas CCR3, CCR4, CXCR, and RUNX1 were increased in FH-MAC compared with co-MAC, with the increase being more evident in the proinflammatory M1-like FH-MAC. Chemokine receptor levels were unrelated to LDL plasma levels at entry, but correlated with age in patients with FH, not in controls. In summary, we demonstrate for first time to our knowledge that MACs from FH-MACs have an inflammatory phenotype that is characterized by the up-regulation of CCR3, CCR4, and CXCR1 under the control of miR-505-3p. These results suggest a chronic inflammatory condition in FH innate immunity cells that is not reverted by standard lipid-lowering treatment.-Escate, R., Mata, P., Cepeda, J.M., Padró, T., Badimon, L. miR-505-3p controls chemokine receptor up-regulation in macrophages: role in familial hypercholesterolemia. FASEB J. 32, 601-612 (2018). www.fasebj.org.
家族性高胆固醇血症(FH)由于终生暴露于高LDL胆固醇水平,而标准的降脂治疗又无法将其充分降低,因而具有很高的早发性动脉粥样硬化风险。炎症介质在动脉粥样硬化病变进展中发挥了作用。在此,我们研究了FH患者的固有免疫细胞是否具有与正常参与者细胞不同的特定促炎表型。为此,我们在FH患者的单核细胞衍生巨噬细胞(FH-MACs)和非FH对照(对照-MACs)中研究了与慢性炎症相关的微小RNA miR-505-3p及其靶基因。基于对阿戈美拉汀-505-3p转染的MACs的基因表达谱PCR阵列分析,我们确定趋化因子受体CCR3、CCR4和CXCR1是受miR-505-3p通过转录因子RUNX1调控的基因。与对照-MAC相比,FH-MAC中miR-505-3p显著下调,而CCR3、CCR4、CXCR和RUNX1则上调,在促炎的M1样FH-MAC中这种上调更为明显。趋化因子受体水平与入组时的血浆LDL水平无关,但与FH患者的年龄相关,而与对照组无关。总之,据我们所知,我们首次证明FH-MACs的巨噬细胞具有一种炎症表型,其特征是在miR-505-3p的控制下CCR3、CCR4和CXCR1上调。这些结果表明FH固有免疫细胞存在慢性炎症状态,且标准降脂治疗无法使其恢复。——埃斯卡特,R.,马塔,P.,塞佩达,J.M.,帕德罗,T.,巴迪蒙,L. miR-505-3p控制巨噬细胞中趋化因子受体上调:在家族性高胆固醇血症中的作用。《美国实验生物学会联合会杂志》32,601 - 612(2018年)。www.fasebj.org